Drug Profile


Alternative Names: Epcitabine; L-dC; LDC300; monoval-LdC; NM-147; NV-02C; Torcitabine; val-L-dC; Valtorcitabine dihydrochloride

Latest Information Update: 02 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idenix Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 28 Sep 2007 Discontinued - Phase-II for Hepatitis B in USA (PO)
  • 18 May 2006 Phase-IIb clinical trials of valtorcitabine + telbivudine for Heptitis B in USA (PO)
  • 11 Jul 2005 Novartis has obtained the right to commercialise valtorcitabine in all areas of the world, Idenix has retained the right to co-promote or co-market in the US, UK, France, Germany, Spain and Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top